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Comprehensive assessment of the safety of olodaterol 5 µg in
the Respimat® device for maintenance treatment of COPD:
comparison with the long-acting β2-agonist formoterol
Andrea Koch1,2, Henrik Watz3, M. Reza Maleki-Yazdi4, Ulrich Bothner 5, Kay Tetzlaff5, Florian Voß5 and Lorcan McGarvey6
This analysis provides a comprehensive clinical assessment of the long-term safety of the licensed dose of olodaterol (5 µg once
daily [QD] via Respimat® inhaler) in patients with chronic obstructive pulmonary disease by exploring the occurrence of
acknowledged side effects of long-acting β2-agonists as well as those included in the olodaterol and formoterol labels. We analysed
pooled data from two replicate, double-blind studies of olodaterol (5 µg QD via Respimat®) compared to formoterol (12 µg twice
daily [BID]) or placebo over 48 weeks (1222.13, NCT00793624; 1222.14, NCT00796653). Patients could continue their background
treatment. The analysis considered adverse events (AEs) typically associated with β2-agonists, including cardiovascular events, as
well as administration-related events. Descriptive statistics were provided for the incidence of AEs and aggregated AEs. The analysis
included 1379 patients: 460 placebo, 459 olodaterol and 460 formoterol; AEs were reported by 70.9, 71.7 and 69.1% of patients,
respectively. Exposure-adjusted incidence rates of cardiac AEs (arrhythmia and myocardial ischaemia) and cough were numerically
lower in the olodaterol group than the formoterol group, while nasopharyngitis, throat irritation, metabolism and psychiatric
disorders were numerically higher in the olodaterol group. The most frequent event in the olodaterol group was nasopharyngitis
(placebo 8.0%; olodaterol 12.9%; formoterol 10.0%). Except for cough (incidence rate ratio of 0.46 [95% conﬁdence interval 0.24,
0.89] in favour of olodaterol), there were no signiﬁcant differences between active groups. In conclusion, olodaterol 5 µg QD was
well tolerated over 48 weeks with a typical β2-agonist safety proﬁle comparable to formoterol 12 µg BID.
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INTRODUCTION
Bronchodilators, including long-acting β2-agonists (LABAs), are
central to the symptom management of chronic obstructive
pulmonary disease (COPD).1 The twice-daily (BID) inhaled LABAs
formoterol and salmeterol have been available for the treatment
of COPD since the late 1990s and effectively improve lung
function, symptoms of breathlessness and quality of life.2 Of the
two agents, formoterol (12 µg BID) also has the beneﬁt of a faster
onset of action.3 Owing to the extensive experience with these
established agents, they have well-deﬁned safety and tolerability
proﬁles that have been used as reference for β2-agonist class
effects when evaluating other LABAs.4,5
Inhaled LABAs are generally well tolerated but have acknowl-
edged class side effects, including palpitations, headache,
nasopharyngitis and tremor.1,6 There are also potential cardiovas-
cular risks such as arrhythmia and myocardial ischaemia
associated with LABAs, particularly in patients with concomitant
cardiac disorders, which are common co-morbidities in patients
with COPD.7
Olodaterol is a novel once-daily (QD) LABA that has recently
been approved and is available to clinicians via the Respimat®
device (Boehringer Ingelheim GmbH & Co. KG, Ingelheim,
Germany) (5 µg QD).8 Given that olodaterol has only been
available since mid-2014, post-marketing experience is currently
limited; however, long-term safety data for olodaterol (5 and 10 µg
QD) are available from a large clinical trial programme.8,9 We
conducted an analysis to speciﬁcally assess the safety proﬁle of
the approved and marketed dose of olodaterol (5 µg QD) in
comparison to formoterol (12 µg BID). This analysis goes beyond a
standard safety review by considering speciﬁc adverse events
(AEs) associated with the class, as well as those included in the
label for formoterol and olodaterol, to provide clinicians with a
clear understanding of its safety proﬁle and place olodaterol into
context with other LABAs. The pooled safety analysis was pre-
speciﬁed but without incidence rates, and additional grouped
terms were added. The higher dose of olodaterol in these studies
(10 µg) has not been discussed in this paper.
RESULTS
A total of 1379 patients were included in this analysis: 460
randomised to placebo, 459 to olodaterol 5 µg and 460 to
formoterol 12 µg. In general, the treatment groups were well
balanced with respect to demographic and baseline patient
characteristics (Table 1), although the placebo group had a slightly
larger proportion of patients with a COPD severity of Global
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Initiative for Chronic Obstructive Lung Disease (GOLD) 4 (10.0
versus 6.8% in the olodaterol group and 8.3% in the formoterol
group). A substantial proportion of patients in each group had
cardiac (18.9, 19.0 and 20.0%, respectively) or vascular (42.0, 41.2
and 43.7%, respectively) co-morbidities, reﬂecting the severity of
COPD in this study patient population.
A greater proportion of patients discontinued treatment in the
placebo group (23.5%) than the olodaterol 5 µg (15.9%) or
formoterol 12 µg (18.0%) groups. A Kaplan–Meier analysis of time
to discontinuation for any reason showed that the probability of
discontinuation was signiﬁcantly higher with placebo than
olodaterol (P = 0.0013) and formoterol (P = 0.0180) throughout
the study (Fig. 1). Discontinuations were similar between
olodaterol and formoterol, with the Kaplan–Meier curve for time
to discontinuation for olodaterol slightly below the one for
formoterol over the whole observational period.
Summary of safety outcomes
Patients with any AE were reported at 70.9, 71.7 and 69.1% in the
placebo, olodaterol and formoterol groups, respectively. The
incidence of serious AEs was slightly lower in the olodaterol and
formoterol groups than with placebo. Ten patients in each group
(2.2%) experienced fatal AEs. The incidence of AEs leading to
discontinuation was lowest in the olodaterol 5 µg group (Fig. 2).
The incidence of investigator-deﬁned drug-related AEs was
lower in the olodaterol 5 µg group (6.1%) than the placebo and
formoterol 12 µg groups (9.1 and 11.1%, respectively).
Cardiovascular AEs
The crude incidences of arrhythmia and myocardial ischaemia
events were lower in the olodaterol 5 µg group than the placebo
and formoterol 12 µg groups (Table 2). Crude incidence of the
combined torsade de pointes/QT prolongation Standardised
MedDRA Query (SMQ) was ﬁve patients (1.1%) in each group. All
cases were QT prolongation reported as an AE in any of the
frequently repeated electrocardiogram study measurements;
there was no occurrence of Torsades de pointes arrhythmia in
any of the treatment groups.
The majority of exposure-adjusted incidence rate ratios (RRs) for
the cardiovascular AE groups (including tachyarrhythmia and
ischaemic heart disease) were lower with olodaterol compared to
formoterol. However, differences were not statistically signiﬁcant
since the 95% conﬁdence intervals (CIs) included 1.0 (Fig. 3).
General AEs and those associated with drug administration. Over-
all, the crude incidences of other AE groups and those associated
with drug administration were similar across the three treatment
Table 1. Demographic and baseline patient characteristics (treated
population)
Characteristics Placebo
(n= 460)
Olodaterol
5 µg
(n= 459)
Formoterol
12 µg
(n= 460)
Male, n (%) 375 (81.5) 364 (79.3) 371 (80.7)
Mean (SD) age, years 63.9 (8.1) 63.7 (8.9) 64.9 (8.4)
Smoking status, n (%)
Ex-smoker 301 (65.4) 303 (66.0) 305 (66.3)
Current smoker 159 (34.6) 156 (34.0) 155 (33.7)
Mean (SD) smoking history,
pack-years
43.7 (25.0) 43.0 (25.0) 45.1 (26.0)
Mean (SD) BMI (kg/m2) 25.2 (5.2) 25.3 (5.7) 24.9 (5.2)
Co-morbidities, n (%)
Cardiac 87 (18.9) 87 (19.0) 92 (20.0)
Vascular 193 (42.0) 189 (41.2) 201 (43.7)
GOLD, n (%)
1 (≥30%) 1 (0.2) 2 (0.4) 3 (0.7)
2 (50–<80%) 242 (52.6) 255 (55.6) 247 (53.7)
3 (30–<50%) 171 (37.2) 171 (37.3) 172 (37.4)
4 (<30%) 46 (10.0) 31 (6.8) 38 (8.3)
Baseline pulmonary medication, n (%)
Any pulmonary medication 377 (82.0) 391 (85.2) 385 (83.7)
SAMA 136 (29.6) 144 (31.4) 133 (28.9)
LAMA 118 (25.7) 117 (25.5) 117 (25.4)
SABA 217 (47.2) 218 (47.5) 220 (47.8)
LABA 170 (37.0) 168 (36.6) 173 (37.6)
Oral β-adrenergics 4 (0.9) 6 (1.3) 2 (0.4)
Leukotriene receptor antagonists 11 (2.4) 9 (2.0) 2 (0.4)
Mucolytics 31 (6.7) 31 (6.8) 34 (7.4)
Oxygen 4 (0.9) 0 (0.0) 1 (0.2)
ICS 227 (49.3) 222 (48.4) 210 (45.7)
Oral steroids 7 (1.5) 12 (2.6) 5 (1.1)
Xanthines 78 (17.0) 88 (19.2) 80 (17.4)
SD standard deviation, BMI body mass index, GOLD Global Initiative for
Chronic Obstructive Lung Disease, SAMA short-acting muscarinic antago-
nist, LAMA long-acting muscarinic antagonist, SABA short-acting β-agonist,
LABA long-acting β2-agonist, ICS inhaled corticosteroid
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Fig. 1 Probability of discontinuation with placebo, olodaterol and
formoterol. Cox regression analysis shows a signiﬁcant difference
from placebo for olodaterol 5 μg (P= 0.0013) and for formoterol
treatment (P= 0.0180)
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Fig. 2 Overall incidence of adverse events (AEs)
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arms (Table 2). The crude incidences of nasopharyngitis and throat
and other application-site irritation were higher in the olodaterol
5 µg group (12.9 and 15.0%, respectively) than placebo (8.0 and
11.3%, respectively) and the formoterol 12 µg group (10.0 and
12.6%, respectively). The crude incidence of cough was lower with
olodaterol (2.8%) than placebo (5.0%) and formoterol (5.9%).
The extent of exposure-adjusted RRs was in line with the
observed crude incidence differences comparing olodaterol 5 µg
to formoterol 12 µg. Olodaterol 5 µg was associated with
numerically higher RRs of nasopharyngitis, throat and other
application-site irritation, metabolism and psychiatric disorders
(Fig. 3). Formoterol was associated with numerically higher RRs for
cough, musculoskeletal, gastrointestinal and nervous system
disorders. However, with the exception of cough (single MedDRA
Preferred Term) and metabolism and nutrition disorders (collec-
tion of AEs in MedDRA System Organ Class), the 95% CIs for RRs of
AEs between olodaterol and formoterol included 1.0 (i.e., were not
statistically signiﬁcant). There were low incidence rates for
metabolic and nutrition disorders System Organ Class (mainly
hypoglycaemia) with no substantial difference in the crude
incidence for olodaterol or formoterol compared to placebo
(Table 2).
Rescue medication. Throughout the 48-week study period,
patients receiving olodaterol 5 µg or formoterol 12 µg took
signiﬁcantly less daytime and night-time rescue medication than
those receiving placebo (P < 0.05). At Week 48, the weekly mean
(standard error [SE]) number of puffs during the daytime was
1.322 (0.068), 1.053 (0.069) and 1.062 (0.069) with placebo,
olodaterol 5 µg and formoterol 12 µg, respectively. The common
baseline mean (SE) was 1.221 (0.039). For night-time rescue
medication use, the weekly mean (SE) number of puffs was 2.023
(0.093), 1.492 (0.093) and 1.582 (0.093) with placebo, olodaterol 5
µg and formoterol 12 µg, respectively. The common baseline
mean (SE) was 1.943 (0.053).
There were no relevant differences between the active
treatment arms in rescue medication usage.
DISCUSSION
Main ﬁndings
This analysis of pooled data from two replicate, 48-week, phase III
studies comparing olodaterol 5 µg QD with formoterol 12 µg BID
or placebo in patients with moderate to very severe COPD (GOLD
2–4) showed that the overall incidence and types of most frequent
AEs were similar in the olodaterol, placebo and formoterol groups.
Nasopharyngitis, which is a known side effect of Striverdi®
Respimat®, occurred more frequently with olodaterol 5 µg than
placebo.8 Importantly, cardiovascular events occurred infrequently
and generally with a similar or lower incidence with olodaterol 5
µg than placebo or formoterol 12 µg. This provides reassurance of
the cardiovascular safety of olodaterol among the β2-agonist class
in COPD treatment.
Interpretation of ﬁndings in relation to previously published work
Our analysis considered AEs typically associated with the inhaled
β2-agonist class. The data originate from randomised controlled
studies in which study medication was added on to existing
background treatment across all groups, allowing the effect of the
maintenance treatment LABA to be tested on top of a realistic
COPD background therapy. The fact that there was no substantial
difference with olodaterol and placebo in the incidence of AEs
supports the acceptable general safety proﬁle of this medication.
The lack of any substantial difference between active treatments
and placebo may have been inﬂuenced, however, by rescue
medication usage; throughout the course of the study, the use of
rescue medication (salbutamol) was higher in the placebo group
than the active treatment arms, increasing patient exposure to the
inherent β2-agonist risks.
The direct comparison of exposure-adjusted AE incidences
between the olodaterol and formoterol groups indicated that
both drugs have a similar safety proﬁle overall. The safety proﬁle
of olodaterol in this analysis also appears similar to that reported
for the LABAs indacaterol5,10 and vilanterol11 in patients with
COPD. Donohue et al. reported that the most common AEs
associated with indacaterol were worsening of COPD,
Table 2. Incidence of cardiovascular, general and administration-
related AEs (formoterol-labelled β2-agonist class side effects)
AE, n (%) Placebo Olodaterol
5 µg
Formoterol
12 µg
(n= 460) (n= 459) (n= 460)
Cardiovascular
Tachyarrhythmias (including
extrasystoles)
16 (3.5) 10 (2.2) 15 (3.3)
Supraventricular (including
atrial ﬁbrillation)
12 (2.6) 5 (1.1) 10 (2.2)
Ventricular 6 (1.3) 5 (1.1) 9 (2.0)
Torsade de pointes/QT
prolongation
5 (1.1) 5 (1.1) 5 (1.1)
Ischaemic heart disease 12 (2.6) 4 (0.9) 7 (1.5)
Myocardial infarction 3 (0.7) 1 (0.2) 4 (0.9)
Other ischaemic heart disease
(non-infarction)
9 (2.0) 3 (0.7) 3 (0.7)
Hypotension 1 (0.2) 0 (0.0) 2 (0.4)
Hypertension 16 (3.5) 14 (3.1) 10 (2.2)
Palpitations 8 (1.7) 4 (0.9) 10 (2.2)
Peripheral oedema 6 (1.3) 8 (1.7) 5 (1.1)
Respiratory and administration related
Cough 23 (5.0) 13 (2.8) 27 (5.9)
Bronchospasm 1 (0.2) 0 (0.0) 2 (0.4)
Nasopharyngitis 37 (8.0) 59 (12.9) 46 (10.0)
Throat and other application-
site irritation
52 (11.3) 69 (15.0) 58 (12.6)
Gastrointestinal
Nausea 7 (1.5) 4 (0.9) 3 (0.7)
Dry mouth 6 (1.3) 7 (1.5) 5 (1.1)
Metabolism
Hypokalaemia 1 (0.2) 0 (0.0) 0 (0.0)
Hyperglycaemia/new-onset
diabetes mellitus
6 (1.3) 7 (1.5) 4 (0.9)
Musculoskeletal
Arthralgia/myalgia/muscle
weakness
46 (10.0) 50 (10.9) 52 (11.3)
Muscle spasm 6 (1.3) 8 (1.7) 10 (2.2)
Nervous system
Dizziness 11 (2.4) 10 (2.2) 10 (2.2)
Tremor 1 (0.2) 2 (0.4) 3 (0.7)
Headache 18 (3.9) 16 (3.5) 16 (3.5)
Psychiatric
Nervousness 1 (0.2) 0 (0.0) 0 (0.0)
Restlessness/agitation 1 (0.2) 0 (0.0) 1 (0.2)
Anxiety 3 (0.7) 3 (0.7) 1 (0.2)
Insomnia 1 (0.2) 5 (1.1) 3 (0.7)
AE adverse event
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nasopharyngitis and headache, and that there was no increase in
the incidence of major adverse cardiovascular events with
indacaterol versus placebo (0.69–1.10% versus 1.44%).10 In an
analysis of the cardiovascular and cerebrovascular safety proﬁles
in patients with COPD, indacaterol was similar to formoterol,
salmeterol, tiotropium and placebo.5
Strengths and limitations of this study
Co-morbidities are common in patients with COPD, including
cardiac, metabolic, psychiatric, neurological and musculoskeletal
disorders,12 and this was indeed the case in our study. Therefore, it
is difﬁcult to establish a causal drug relationship to speciﬁc AEs
when the population is at high risk of such events merely from
their pre-existing diseases. Consequently, this analysis included all
reported AEs irrespective of the study investigators’ assessment of
causality. For information, the incidence of drug-related AEs as
detailed by the study investigators was low and not substantially
different for olodaterol, placebo and formoterol (6.1, 9.1 and
11.1%, respectively).
Patient selection and treatment exposure in these studies were
close to real-world data. Given the fact that large, long-term,
blinded, randomised controlled trials are extremely difﬁcult and
expensive to conduct in COPD, a 1-year observation may not be
long enough to detect very rare AEs. This is, however, usually the
domain of post-marketing pharmacovigilance and not in scope of
an everyday safety proﬁle comparison. Overall, the nature and
frequency of events reported in our studies were consistent with
the disease under study and thus conﬁrmed that olodaterol 5 µg
QD has an acceptable safety and tolerability proﬁle in patients
with moderate to severe COPD, similar to that of the well-
established LABA formoterol 12 µg BID.
Implications for future research, policy and practice
These safety proﬁling data add support to the previously
published data with olodaterol.9 However, as olodaterol is
relatively new to the market (as with other once-daily LABAs),
continued assessment will be required to ensure that its safety
proﬁle remains clearly deﬁned.
CONCLUSIONS
Olodaterol 5 µg QD via Respimat® was well tolerated over
48 weeks, with a typical β2-agonist safety proﬁle comparable to
formoterol 12 µg BID dry powder inhalation. The tolerability is also
supported by the lowest discontinuation rate for olodaterol
among all treatments. Based on blinded, randomised, parallel-
group, placebo-controlled and formoterol-controlled, long-term
clinical data, the incidence of AEs was similar with olodaterol 5 µg
QD for serious AEs and cardiovascular AEs compared with
formoterol 12 µg BID. Mortality was low and similar across all
treatment groups (approximately 2.2%, which is a usual mortality
rate over 1 year in a COPD population). These data give reassuring
information about the safety of olodaterol as a LABA option in
moderate to severe COPD maintenance treatment. The data from
this analysis suggest that olodaterol is an adequate alternative to
formoterol for COPD maintenance treatment.
METHODS
This analysis included pooled data from two replicate, multicentre, double-
blind, phase III studies of olodaterol (5 µg QD and 10 µg QD via Respimat®)
compared to formoterol (12 µg BID dry powder inhalation) or placebo over
48 weeks (1222.13, NCT00793624; 1222.14, NCT00796653). Both devices
(the olodaterol Respimat® and the formoterol dry powder inhaler) were
used together with the respective placebo device (double-dummy
administration). The blinded formoterol study medication contained
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Fig. 3 Forest plot showing the exposure-adjusted rate and ratio for adverse events (AEs) of interest comparing olodaterol 5 µg with
formoterol 12 µg. CI conﬁdence interval
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Foradil®.13 The studies included patients with moderate to very severe
COPD (GOLD 2–4) who were aged ≥40 years and were current or ex-
smokers (with a smoking history >10 pack-years). Patients with a history of
asthma were excluded. With the exception of LABAs, patients continued
with their existing COPD maintenance treatment, including short-acting
muscarinic antagonists, long-acting muscarinic antagonists, corticosteroids
and xanthines. All patients were provided with salbutamol as rescue
medication. Full details of the study methodology have been published
elsewhere.14 In total across the two studies, 1838 patients were
randomised to treatment (225 to placebo, 227 to olodaterol 5 µg, 225 to
olodaterol 10 µg and 227 to formoterol 12 µg in study 1222.13; 235 to
placebo, 232 to olodaterol 5 µg, 234 to olodaterol 10 µg and 233 to
formoterol 12 µg in study 1222.14). This analysis focuses on the licensed
dose of olodaterol (5 µg QD via Respimat®).
After a baseline visit, patients attended study visits following 2, 6, 12, 18,
24, 32, 40 and 48 weeks of treatment. AEs were recorded throughout the
study, irrespective of investigator-reported causality.
Ethics
The studies were performed in accordance with the Declaration of Helsinki,
International Conference on Harmonisation Harmonised Tripartite Guide-
line for Good Clinical Practice and local regulations. The protocols were
approved by the authorities and ethics committees of the respective
institutions, and signed informed consent was obtained from all patients.
Selection of outcomes
Outcomes for comparing olodaterol with formoterol in this analysis were
selected based on the typical β2-agonist class side effects, as exempliﬁed
by the formoterol (Foradil®) label.13 Side effects in the olodaterol label were
also included in the analysis; however, given the much shorter time that
olodaterol has been available, the range of events is less extensive than for
formoterol.
The list of labelled side effects in the formoterol Summary of Product
Characteristics was used as a basis to determine safety search terms, as
Table 3. Label-recognised β2-agonist-related side-effect terms for formoterol and olodaterol8,13 and database event search terms
Organ/body system Foradil® (formoterol) SPC side effects Striverdi® Respimat®
(olodaterol) SPC side effects
Study database event search terms
(groups)
Cardiovascular Tachycardia, cardiac arrhythmias e.g., atrial
ﬁbrillation, supraventricular tachycardia,
extrasystoles
– Tachyarrhythmias (including
supraventricular and ventricular
tachyarrhythmias) (SMQ)
• Supraventricular tachyarrhythmias (SMQ)
• Ventricular tachyarrhythmias (SMQ)
Palpitations – Palpitations (PV)
Angina pectoris – Ischaemic heart disease (SMQ)
•Myocardial infarction (SMQ)
•Other ischaemic heart disease (SMQ)
Prolongation of QTc interval – Torsade de pointes/QT prolongation (SMQ)
Increased blood pressure (including
hypertension)
Hypertension Hypertension (SMQ)
Variations in blood pressure – Hypotension (PV)
Peripheral oedema – Peripheral oedema (PV)
Respiratory and
administration related
Bronchospasm, acute asthma exacerbationa – Bronchospasm (broad) (PV)
Paradoxical bronchospasm – Bronchospasm paradoxical (PT)
Throat irritation – Throat and other application site irritation
(PV)
Cough – Cough (PT)
– Nasopharyngitis Nasopharyngitis (PT)
Gastrointestinal Dry mouth – Dry mouth (PV)
Nausea – Nausea (PV)
Metabolic Hypokalaemia – Hypokalaemia (PV)
Hyperglycaemia – Hyperglycaemia/new–onset diabetes
mellitus (SMQ)
Musculoskeletal Myalgia Arthralgia Arthralgia/myalgia/muscle weakness (PV)
Muscle cramp – Muscle spasm (PV)
Nervous system Headache – Headache (PV)
Tremor – Tremor (PV)
Dizziness Dizziness Dizziness (PV)
Dysgeusia – Taste disorders (PV)
Psychiatric Agitation – Restlessness/agitation (PV)
Anxiety – Anxiety (PV)
Nervousness – Nervousness (PV)
Restlessness – Restlessness/agitation (PV)
Insomnia – Insomnia (PV)
MedDRA Medical Dictionary for Regulatory Activities, PT MedDRA preferred term, PV sponsor-deﬁned pharmacovigilance end point, SMQ standardised
MedDRA query
a Not speciﬁc to COPD indication, relates to bronchospasm (note: formoterol has an indication and label for both asthma and COPD)
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shown in Table 3. Although not included in the formoterol label,
nasopharyngitis was also evaluated in this analysis, as it was reported
with olodaterol at a higher frequency than placebo in the clinical
programme. While myocardial infarction is not included in the label for
either formoterol or olodaterol, it was considered an important event for
inclusion in this analysis. The formoterol-labelled events of bronchospasm
paradoxical and taste disorders (dysgeusia) do not appear in the results as
there were no occurrences in the study database in any treatment group.
Events relating to hypersensitivity were not regarded typical to β2-agonist
pharmacology but rather substance speciﬁc and, therefore, are not
considered as part of the scope of this article.
Statistical methodology
Descriptive statistics were provided for the incidence of AEs and
aggregated AE groups (based on Medical Dictionary for Regulatory
Activities SMQs, or sponsor-deﬁned pharmacovigilance end points where
SMQs were not available for the medical AE concept of interest). AE
incidences are described with their crude incidence (percentage of
patients with the event out of all patients in the treatment group)
and exposure-adjusted incidence rate (number of events per 100
patient-years at risk with the drug) in order to adjust for different
exposure between the treatment arms in case of differential study
discontinuation. Exposure-adjusted RRs and their 95% CIs are calculated
based on a Cochran–Mantel–Haenszel method stratiﬁed by study to
compare olodaterol versus formoterol treatment groups. AEs of interest are
displayed with their RR and 95% CI in a forest plot. Time to early
discontinuation of patients from the study was compared with a Cox
regression analysis of treatment effect using baseline long-acting
muscarinic antagonist concomitant medication (tiotropium) use as a
stratiﬁcation factor. This is a post hoc analysis and no formal statistical
testing of hypotheses was performed. The assessment of statistical
signiﬁcance via 95% CIs of the RR is, therefore, considered exploratory
and no adjustment for multiple testing was done.
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